Despite advances in the understanding of disease pathogenesis, and the increased availability of treatment options, the prevalence of ESRD continues to rise in people living with T2DM [6]
The China GLP-1 market is experiencing growth supported by a rising prevalence of metabolic disorders and increasing investments in healthcare modernization
Despite likely being a similar tier as GLP-1 RAs and SGLT2is for many patient insurances, this elevated AWP is important to note for patients with co-insurances, deductibles, the Medicare coverage gap, patients without insurance, and for the total cost of healthcare
Microdosing involves using doses below manufacturer-recommended levels without supporting clinical trial data on efficacy or safety
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
5-7% Study after study has shown that patients with prediabetes who lost even 5-7% of their weight prevented progression to type 2 diabetes
